LitAlert ~~ GeneLit.com

    • Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
    • Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi A.
    • BMC Cancer. 2020 Jun 3;20(1):507. doi: 10.1186/s12885-020-06948-5.

    • Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study.
    • Yoshihara K, Enomoto T, Aoki D, Watanabe Y, Kigawa J, Takeshima N, Inomata H, Hattori K, Jinushi M, Tsuda H, Sugiyama T.
    • Cancer Sci. 2020 Jun 3. doi: 10.1111/cas.14513. Epub ahead of print.

    • Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.
    • Randall Armel S, Volenik A, Demsky R, Malcolmson J, Maganti M, McCuaig J.
    • Gynecol Oncol. 2020 Jun 3. pii: S0090-8258(20)31082-9. doi: 10.1016/j.ygyno.2020.05.014. [Epub ahead of print]

    • Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines.
    • Fortuno C, Mester J, Pesaran T, Weitzel JN, Dolinsky J, Yussuf A, McGoldrick K, Garber JE, Savage SA, Khincha PP, Gareth Evans D, Achatz MI, Nichols KE, Maxwell K, Schiffman JD, Sandoval R; Li-Fraumeni Exploration (LIFE) Consortium, James PA, Spurdle AB.
    • Hum Mutat. 2020 Jun 2. doi: 10.1002/humu.24060. Epub ahead of print.

    • Intraoperative radiotherapy in early breast cancer: observational comparison with whole breast radiotherapy.
    • Oliver Guillén JR, Hernando Almudi E, Molina Osorio G, Ibañez Carreras R, Font Gómez JA, Vicente Gómez I, García Mur C, Casamayor Franco MC.
    • Cir Esp. 2020 May 31:S0009-739X(20)30161-5. English, Spanish. doi: 10.1016/j.ciresp.2020.04.024.

    • Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
    • Ruscito I, Bellati F, Ray-Coquard I, Mirza MR, du Bois A, Gasparri ML, Costanzi F, De Marco MP, Nuti M, Caserta D, Pignata S, Dorigo O, Sehouli J, Braicu EI.
    • Cancer Treat Rev. 2020 May 26;87:102040. doi: 10.1016/j.ctrv.2020.102040. Epub ahead of print.
    • Review

    • The Melanoma and Breast Cancer Association: An Overview of their 'Second Primary Cancers' and the Epidemiological, Genetic and Biological correlations.
    • Jeyakumar A, Chua T, Lam AK, Gopalan V.
    • Crit Rev Oncol Hematol. 2020 May 22;152:102989. doi: 10.1016/j.critrevonc.2020.102989. Epub ahead of print.
    • Review

    • Evaluation of breast screening strategies in a high risk breast and ovarian cancer clinic.
    • Knisely AT, Stewart ME, Garcia C, Thomas MH, Modesitt SC, Ring KL.
    • Gynecol Oncol Rep. 2020 May 22;33:100587. doi: 10.1016/j.gore.2020.100587.

    • Germline variants and phenotypic spectrum in a Canadian cohort of individuals with diffuse gastric cancer.
    • Aronson M, Swallow C, Govindarajan A, Semotiuk K, Cohen Z, Kaurah P, Velsher L, Ambus I, Buckley K, Forster-Gibson C, Meschino WS, Blumenthal A, Kim RH, Brar S.
    • Curr Oncol. 2020 Apr;27(2):e182-e190. doi: 10.3747/co.27.5663. Epub 2020 May 1.

    • Characteristics of early-onset pancreatic cancer and its association with familial pancreatic cancer and hereditary pancreatic cancer syndromes.
    • Eguchi H, Kobayashi S, Gotoh K, Noda T, Doki Y.
    • Ann Gastroenterol Surg. 2020 Mar 27;4(3):229-233. doi: 10.1002/ags3.12326.